Loading
No description yet: the sentence for this tag has not been written. 11 records carry it: 4 people, 4 technologies, 3 terms.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Christopher M. Booth Professor of Oncology and Public Health Sciences, Queen's University; Medical Oncologist, Kingston Health Sciences Centre · Queen's University / Kingston Health Sciences Centre Oncologist who co-led CHALLENGE and founded Common Sense Oncology to refocus trials on outcomes that matter to patients. | Colorectal cancer | none | evidence, exercise | ||
David Baldwin Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust; Honorary Professor of Medicine, University of Nottingham; Lead Clinician for Lung Cancer, NHS England · Nottingham University Hospitals Cancer Centre (City Hospital) The Nottingham chest physician who chairs the UK clinical expert group for lung cancer and advises the National Screening Committee: the person whose job it is to turn the screening evidence into an NHS service. | Non-small-cell lung cancer, Lung cancer | none | lung, screening, uk | ||
Employment rights with cancer in the United Kingdom Schedule 1 of the Equality Act 2010 says in one sentence that "Cancer, HIV infection and multiple sclerosis are each a disability", so protection applies from the moment of diagnosis rather than when the illness starts to limit anything. That brings the employer's duty to make reasonable adjustments, and Statutory Sick Pay of £123.25 a week for up to 28 weeks. | HR-positive / HER2-negative breast cancer, Colorectal cancer, Prostate cancer | none | rejuvenation, survivorship, psychosocial | ||
Employment rights with cancer in the United States Federal regulation states that "cancer substantially limits normal cell growth", and the statute counts an impairment in remission if it would substantially limit a major life activity when active. The Americans with Disabilities Act reaches employers with 15 or more employees; unpaid job-protected leave under the Family and Medical Leave Act is 12 workweeks a year. | HR-positive / HER2-negative breast cancer, Colorectal cancer, Prostate cancer | none | rejuvenation, survivorship, psychosocial | ||
Insurance, mortgages and the right to be forgotten Nine European Union countries have passed laws giving people who have had cancer the right not to declare it when applying for a loan or insurance after a set period, commonly five to ten years for adults and five for a cancer diagnosed young. Where the laws have been in force longest, acceptance rates are high and the strain on insurers is reported as minimal. | Hodgkin lymphoma, Testicular germ cell tumours, Melanoma | none | rejuvenation, survivorship, psychosocial | ||
Jonathan Benger Chief Executive of NICE (since December 2025) · National Institute for Health and Care Excellence Emergency physician who became Chief Executive of NICE, the body that appraises new cancer medicines and issues clinical guidance for the NHS, in December 2025. | none | none | leadership, clinician-scientist, hta | ||
Oncology drug pricing and price transparency New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated. | none | none | none | ||
Oncology workforce There are not enough oncologists, radiation therapists, pathologists, oncology nurses and pharmacists for the growing number of patients, in rich countries and especially in poor ones; burnout, geography and training pipelines shape who receives care. | none | none | none | ||
Rachel Michaelson-Cohen Gynaecologist and medical geneticist, Shaare Zedek Medical Center; chair of the Israeli Consortium harmonising national BRCA carrier care · Shaare Zedek Medical Center Led the work of turning nine Israeli high-risk clinics, which were each doing something different, into one national protocol for looking after the carriers the screening programme keeps finding. | HR-positive / HER2-negative breast cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma | none | clinician-scientist, genetics | ||
What has actually been implemented since those trials, and what has not The trials finished years ago and most people being treated for cancer are still not asked their symptoms between appointments. The clearest thing that changed is a United States payment model that now requires practices to collect them. | Non-small-cell lung cancer, Colorectal cancer, HR-positive / HER2-negative breast cancer | none | rejuvenation, survivorship, measurement | ||
WHO Essential Medicines List for cancer The World Health Organization's list of medicines every health system should provide, which now includes about 60 cancer drugs from cyclophosphamide and cisplatin to trastuzumab, imatinib and PD-1 inhibitors, guiding procurement and pricing in lower-income countries. | none | none | global |